Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 3/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.37 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29393338 | 1.00 | PYCR1 (0.47) | PYCR1KDM1ADGAT1PDPK1AKR1B1 | |
| SCHEMBL20465750 | 1.00 | PYCR1 (0.47) | PYCR1KDM1ADGAT1PDPK1AKR1B1 | |
| SCHEMBL8736491 | 0.85 | CSNK2A1 (0.44) | PYCR1KDM1ADGAT1PDPK1AKR1B1 | |
| SCHEMBL2298211 | 0.82 | PDPK1 (0.45) | PYCR1KDM1ADGAT1PDPK1AKR1B1 | |
| SCHEMBL15543972 | 0.82 | PYCR1 (0.45) | PYCR1KDM1ADGAT1PDPK1AKR1B1 | |
| SCHEMBL31448605 | 0.81 | PYCR1 (0.47) | PYCR1KDM1ADGAT1PDPK1AKR1B1 | |
| SCHEMBL138081 | 0.81 | DPP4 (0.41) | PYCR1KDM1ADGAT1KDM1BNPC1 | |
| SCHEMBL15806743 | 0.81 | PYCR1 (0.47) | PYCR1KDM1ADGAT1PDPK1AKR1B1 | |
| SCHEMBL507839 | 0.79 | PYCR1 (0.46) | PYCR1KDM1ADGAT1PDPK1AKR1B1 | |
| SCHEMBL110765 | 0.79 | PYCR1 (0.46) | PYCR1KDM1ADGAT1PDPK1AKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119912847-A | Composite coating and application thereof | 万华化学集团股份有限公司 | 2025-05-02 | — | — | CN | claimed |
| EP-3112340-B1 | METHOD FOR PRODUCING 4-BORONO-L-PHENYLALANINE HAVING 18F ATOM INTRODUCED THEREINTO, AND PRECURSOR OF 4-BORONO-L-PHENYLALANINE HAVING 18F ATOM INTRODUCED THEREINTO | STELLA PHARMA CORP (JP) | 2020-07-15 | — | — | EP | claimed |
| CN-1047377-C | Preparation method of 2-fluor-4-bromotoluene, 2-fluor-4-bromo benzyl bromide and its 2-fluor-4-bromo benzyl bromide | FUXIN SPECIAL CHEMICALS CO LTD (CN) | 1999-12-15 | — | — | CN | claimed |
| CN-1157812-A | Preparation method of 2-fluor-4-bromotoluene, 2-fluor-4-bromo benzyl bromide and its 2-fluor-4-bromo benzyl bromide | FUXIN SPECIAL CHEMICALS CO LTD (CN) | 1997-08-27 | — | — | CN | claimed |
| JP-1203369-A | — | — | None | — | — | JP | disclosed |
| CN-122010944-A | TBC1D 2-targeted aromatic methyl alkenyl matrine derivative and preparation method and application thereof | 广西大学 | 2026-05-12 | — | — | CN | disclosed |
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | LILLY CO ELI (US) | 2026-04-23 | — | — | US | disclosed |
| US-20260070914-A1 | SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZIN-2-AMINES AS CDK2 AND CDK4 INHIBITORS | INCYTE CORP (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4271674-B9 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12570642-B2 | GLP-IR modulating compounds | GILEAD SCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260062420-A1 | NOVEL DPP1 INHIBITORS AND USES THEREOF | INSMED INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4691554-A2 | GLP-1R MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| WO-1986004895-A1 | FLUOROBENZENE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1986-08-28 | — | — | WO | disclosed |
| US-4581366-A | Aldose reductase inhibition by spiro indoline derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-04-08 | — | — | US | disclosed |
| US-4567278-A | Process for racemizing certain spiro compounds | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-01-28 | — | — | US | disclosed |
| EP-0168181-A1 | Cyclic amides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1986-01-15 | — | — | EP | disclosed |
| US-4539329-A | 7'-Trifluoromethyl-spiro[imidazolidine-4,3'-indoline]-2,2',5-triones as aldose reductase inhibitors | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1985-09-03 | — | — | US | disclosed |
| EP-0125090-A2 | Indoline derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-11-14 | — | — | EP | disclosed |
| EP-0115679-A1 | Chemical process | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-08-15 | — | — | EP | disclosed |
| EP-0101149-A1 | Fluoroalkyl indoline derivatives for pharmaceutical use | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260070914-A1 | SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZIN-2-AMINES AS CDK2 AND CDK4 INHIBITORS | CCNA1, CCNO, CDK1 | PYCR1 989/4885KDM1A 2828/4885DGAT1 3464/4885 |
| US-20260108546-A1 | GIP RECEPTOR AGONIST COMPOUNDS | GIPR, GLP1R, GCGR | PYCR1 1507/4885KDM1A 4614/4885DGAT1 1428/4885 |
| US-20260062420-A1 | NOVEL DPP1 INHIBITORS AND USES THEREOF | DPP4, DPP3, DPP7 | PYCR1 3303/4885KDM1A 672/4885DGAT1 2118/4885 |
| US-12570642-B2 | GLP-IR modulating compounds | GLP1R, GIPR, GPR119 | PYCR1 1689/4885KDM1A 2564/4885DGAT1 1008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.